Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).
Company Details
- Employees
- 18
- Founded
- -
- Address
- 12250 El Camino Real Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- emeraldbio.life
- Keywords
- Provider jobs.
- HQ
- San Diego, CA
Skye Bioscience Inc. Questions
Skye Bioscience Inc.'s website is emeraldbio.life
Skye Bioscience Inc.'s LinkedIn profile is https://www.linkedin.com/company/skyebioscience
Skye Bioscience Inc. has
18 employees.
View email and phone details for 18
employees at Skye Bioscience Inc..
Skye Bioscience Inc.'s industry is
Biotechnology Research
Skye Bioscience Inc.'s top competitors are
Candid Therapeutics,
Life Biosciences,
Jazz Pharmaceuticals,
Enterprise Therapeutics,
Tg Therapeutics, Inc.,
Skye Biologics, Inc.,
Wave Life Sciences,
Ovid Therapeutics,
Anavex Life Sciences,
Lexeo Therapeutics.
Skye Bioscience Inc.'s categories are Biotechnology Research
Skye Bioscience Inc.'s founding year is 2011
